Finance

Lists
Q2 2026 earnings • released • EPS beat +1.32% • Revenue beat +2.46%
See results
HCA:NYSE
HCA Healthcare Inc
$382.19
+1.51%
(+5.69) 1D
$382.19
0.00% (0.00)
After hours
Closed: Jul 24, 4:00:08 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for HCA...
Open
$381.53
High
$399.00
Low
$376.48
Mkt. cap
84.78B
Avg. vol.
1.67M
Volume
2.70M
Dividend
0.82%
Quarterly dividend
$0.78
Ex-dividend date
Jun 16, 2026
P/E ratio
13.14
52-wk high
$556.52
52-wk low
$330.00
EPS
$29.08
Beta
1.12
Shares outstanding
221.84M
No. of employees
275K
Open
$381.53
High
$399.00
Low
$376.48
Mkt. cap
84.78B
Avg. vol.
1.67M
Volume
2.70M
Dividend
0.82%
Quarterly dividend
$0.78
Ex-dividend date
Jun 16, 2026
P/E ratio
13.14
52-wk high
$556.52
52-wk low
$330.00
EPS
$29.08
Beta
1.12
Shares outstanding
221.84M
No. of employees
275K
News stories
From sources across the web
Profile
HCA Healthcare, Inc. is an American global for-profit operator of health care facilities that was founded in 1968. It is based in Nashville, Tennessee, and, as of May 2020, owned and operated 186 hospitals and approximately 2,400 sites of care, including surgery centers, freestanding emergency rooms, urgent care centers and physician clinics in 20 states and the United Kingdom. As of 2024, HCA Healthcare is ranked #61 on the Fortune 500 rankings of the largest United States corporations by total revenue. In the 1990s, the company engaged in illegal accounting and other crimes that resulted in the payment of more than $2 billion in federal fines and other penalties, and the dismissal of the CEO Rick Scott by the board of directors. Wikipedia
About HCA Healthcare Inc
CEOSamuel N. Hazen
Employees275K
Founded1968
HeadquartersNashville, Tennessee, United States
SectorHealth care provider
Websitehcahealthcare.com
Analyst ratings
Based on 17 analysts giving stock ratings to HCA in the past 3 months
Buy
Buy
10
Hold
6
Sell
1
12-month forecast
Based on 17 Wall Street analysts offering 12 month price targets for HCA in the last 3 months.
Highest
Current $382.19
$558.00 (+46.00%)
Average
$461.20 (+20.67%)
Lowest
$369.00 (-3.45%)
Analyst
Recommendation
Action
Price target
Projected
Date
Stephen Baxter
Wells Fargo
Hold
Maintained
$369.00
-3.5%
07/20/2026
Andrew Mok CFA
Barclays
Hold
Reiterated
$402.00
+5.2%
07/15/2026
Scott Fidel
Goldman Sachs
Buy
Maintained
$558.00
+46%
07/14/2026
Andrew Cooper
Raymond James
Hold
Reiterated
-
-
07/15/2026
Ben Hendrix
RBC Capital
Buy
Maintained
$435.00
+13.8%
07/14/2026
Craig Hettenbach
Morgan Stanley
Sell
Maintained
$425.00
+11.2%
07/14/2026
Kevin Fischbeck
Bank of America Securities
Hold
Reiterated
$370.00
-3.2%
07/14/2026
Brian Tanquilut
Jefferies
Buy
Maintained
$450.00
+17.7%
07/14/2026
David S Macdonald
Truist Financial
Buy
Maintained
-
-
07/14/2026
Sarah James
Cantor Fitzgerald
Buy
Maintained
$525.00
+37.4%
07/14/2026
Matthew Gillmor CFA
KeyBanc
Buy
Maintained
$475.00
+24.3%
07/14/2026
Ann Hynes
Mizuho Securities
Buy
Maintained
$525.00
+37.4%
07/13/2026
Ryan Langston
TD Cowen
Buy
Maintained
$431.00
+12.8%
06/25/2026
Lance Wilkes
Bernstein
Hold
Maintained
$413.00
+8.1%
06/09/2026
Benjamin Rossi
J.P. Morgan
Hold
Maintained
$490.00
+28.2%
05/22/2026
Unknown Analyst
Stephens
Buy
Reiterated
$530.00
+38.7%
04/27/2026
Raj Kumar CFA
Stephens
Buy
Reiterated
$530.00
+38.7%
04/27/2026
Michael Wiederhorn
Oppenheimer
Buy
Reiterated
$520.00
+36.1%
04/27/2026
Courtney Breen
Bernstein
Hold
Maintained
$541.00
+41.6%
03/30/2026
A.J. Rice
UBS
Buy
Maintained
$635.00
+66.1%
02/23/2026
Last report
Jul 24, 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
$7.59 / $7.49
+1.32%beat
Revenue / Est. (USD)
20.23B / 19.74B
+2.46%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
19.16B
19.51B
19.11B
20.23B
Cost of goods sold
11.15B
11.34B
11.14B
-
Cost of revenue
11.15B
11.34B
11.14B
-
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
-
1.03B
-
-
Operating expense
5.05B
5.00B
5.11B
-
Total operating expenses
16.20B
16.34B
16.25B
-
Operating income
2.96B
3.18B
2.86B
-
Other non operating income
-
-
-
-
EBT including unusual items
2.42B
2.67B
2.29B
-
EBT excluding unusual items
2.42B
2.63B
2.29B
-
Income tax expense
515.00M
509.00M
430.00M
564.00M
Effective tax rate
21.30%
19.05%
18.80%
-
Other operating expenses
4.16B
3.06B
4.18B
-
Net income
1.64B
1.88B
1.62B
1.70B
Net profit margin
8.57%
9.62%
8.48%
-
Earnings per share
6.96
8.01
7.15
7.59
Interest and investment income
-
-
-
-
Interest expense
-561.00M
-572.00M
-584.00M
-599.00M
Net interest expenses
-561.00M
-572.00M
-584.00M
-
Depreciation and amortization charges
889.00M
911.00M
930.00M
-
EBITDA
3.85B
4.09B
3.79B
4.01B
Gain or loss from assets sale
2.00M
-41.00M
1.00M
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Create a portfolio
Create a task
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer